LGALS9 and neoplasm: Additionally, he investigates recurrence risk assessment in SCLC, identifying Galectin-9 (Gal-9) in TME and (tumor-infiltrating lymphocytes)TILs as a promising predictive immune biomarker, with Gal-9 expression levels correlating significantly with the immune risk score (36).